Additionally, the clinical use of bortezomib-a proteasome inhibitor known to inhibit NF-κB—in the treatment of myeloma, demonstrates the importance of the constitutive activation of the NF-κB-pathway in the pathogenesis of myeloma [5,6]. Here, NFKB1 is linked to plasma cell myeloma.